(Q39192200)

9 September 2017

title

Targeted Treatment of Brain Metastases (English)

1 reference

9 September 2017

Nicole Shonka

1

1 reference

9 September 2017

Vyshak Alva Venur

series ordinal

2

1 reference

9 September 2017

Manmeet S Ahluwalia

series ordinal

3

1 reference

9 September 2017

publication date

1 April 2017

1 reference

Current Neurology and Neuroscience Reports

9 September 2017

published in

1 reference

9 September 2017

volume

17

1 reference

9 September 2017

issue

4

1 reference

9 September 2017

page(s)

37

1 reference

Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Melanoma central nervous system metastases: current approaches, challenges, and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Prognostic scores for brain metastasis patients: use in clinical practice and trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Targeted Therapy in Brain Metastases: Ready for Primetime?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Cranial irradiation after surgical excision of brain metastases in melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Determinants of outcome in melanoma patients with cerebral metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): ...

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

21 January 2018

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Leptomeningeal metastasis: survival and prognostic factors in 155 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Metastatic behavior of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Breast cancer brain metastases: biology and new clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Metastatic breast cancer subtypes and central nervous system metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Trastuzumab: updated mechanisms of action and resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

The discovery of lapatinib (GW572016).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Targeted Therapies for Brain Metastases from Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Activity of T-DM1 in Her2-positive breast cancer brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

PI3K/Akt/mTOR inhibitors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Breast cancer brain metastases: the last frontier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

BRAF, a target in melanoma: implications for solid tumor drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0741-2

Prognostic factors for survival in melanoma patients with brain metastases

21 January 2018

1 reference

PubMed

12 December 2020

Updates on the management of breast cancer brain metastases

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?

1 reference

PubMed

12 December 2020

10.1007/S11910-017-0741-2

Identifiers

DOI

1 reference

9 September 2017

1 reference